PR-2402Helix PharmaRamp-up

Clinical Data Platform — Phase 2

Discovery · TimeAndMaterials · Feb 1, 2026 → Nov 15, 2026

Project at watch

2 concerns: Budget, Risks.

Health drivers

Signals contributing to overall project health.

  • High
    Budget
    Burn 16% above plan.
  • Medium
    Risks
    1 open High-severity risk.

Financial health

Burn vs. plan, margin now and at completion.

Total budget
$6,800,000
Actual cost
$2,140,000
Planned value (BCWS)
$1,850,000
Earned value (BCWP)
$1,780,000
Estimate to complete
$4,900,000
Remaining budget
$4,660,000
Burn vs plan
116%
Current margin
-20%
Forecast margin
-4%
Over budget

Team

Engagement leadership. Full allocations land with the resource service.

Client
Helix Pharma
Industry
Life Sciences
Account owner
Priya Raghavan
Partner
Priya Raghavan
Project manager
Hiroshi Tanaka

Per-resource allocations and over/underutilization land with the resource-planning slice.

Readiness milestones

Kickoff, charter sign-off, and staffing readiness milestones.

No milestones recorded.

Risks & change events

Open risks and recent changes affecting scope, schedule, or staffing.

Open risks

  • High
    Regulatory review extending discovery by 3 weeks
    Schedule · 70% likely · FDA pre-submission slip cascades into Phase 2
  • Medium
    Data engineering lead on extended leave from May 12
    Staffing · 90% likely · Loss of single specialist on critical path

Recent change events

  • Schedule
    FDA pre-submission slipped to W22
    Apr 28, 2026 · +3 weeks
  • Staffing
    Lead data engineer reassigned
    Apr 25, 2026 · Single point of failure
  • Scope
    Two additional source systems added
    Apr 19, 2026 · +$220k effort

Leadership actions

Recommended interventions surfaced by health signals.

  • Medium
    Verify staffing readiness before start date.
    Ramp-up phase: confirm role coverage and start-date readiness.